Pancreas Volume and Diabetes Status Following Pancreatectomy

Using Pancreatic Volumetric to Determine the Onset of Diabetes Mellitus and Postoperative Outcomes After Pancreatectomy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02823678

Enrollment

100

Registered

2016-07-06

Start date

2013-10-31

Completion date

2021-12-31

Last updated

2017-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Neoplasms

Brief summary

This study will enroll 100 patients scheduled to undergo a pancreatectomy. The primary objective is to develop a scoring system using pancreatic volume measured by CT scan and intraoperative measurements of the pancreas parenchyma to predict the onset of diabetes mellitus after a pancreatectomy. The investigators will also monitor patients with pre-existing diabetes to see if their diabetes worsens or improves.

Detailed description

The primary objective is to develop a scoring system using pancreatic volume measured by CT scan and intraoperative measurements of the pancreas parenchyma to predict the onset of diabetes mellitus after a pancreatectomy. The investigators will also monitor patients with pre-existing diabetes to see if their diabetes worsens or improves. Patients will be followed up to one year to track their diabetes status, postoperative outcomes and quality of life.

Interventions

PROCEDUREPancreatectomy

Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients undergoing pancreatectomy at our institution (e.g., pancreaticoduodenectomy, distal pancreatectomy, distal pancreatectomy and splenectomy, central pancreatectomy).

Exclusion criteria

* All patients who are on steroids or other medications whose potential side effects include development of diabetes mellitus or elevated blood glucose. * Pregnant or nursing women. * Patients with uncontrolled diabetes (HbA1c \>8%).

Design outcomes

Primary

Measure	Time frame
Percent resected volume of pancreas and diabetes development	Postoperative up to one year

Secondary

Measure	Time frame
QLQ-C30 Quality of Life Health Questionnaire	Postoperative up to one year
Blood glucose control	Postoperative up to one year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026